乳腺癌患者新辅助化疗预后不良的影响因素

Influencing factors of poor prognosis in patients with breast cancer after neoadjuvant chemotherapy

目的探讨乳腺癌患者新辅助化疗预后不良的影响因素。方法抽取2018年6月至2020年2月周口市中医院107例接受新辅助化疗的乳腺癌患者为研究对象,于治疗6个周期后随访1年,评估所有患者预后情况。设计基线资料调查表,记录患者基线资料,分析乳腺癌患者新辅助化疗预后不良的影响因素。结果术后随访1年,107例乳腺癌患者中病死22例(20.56%),纳入病死组;其余85例纳入生存组。病死组TNM分期为Ⅲ期占比高于生存组,体质指数(BMI)、血清人体表皮生长因子受体2(HER2)水平、血清透明质酸(HA)水平高于生存组(P均<0.05)。Cox回归分析结果显示,TNM分期为Ⅲ期、HER2阳性、BMI与血清HA水平高是乳腺癌患者新辅助化疗预后不良的影响因子(P<0.05)。结论乳腺癌患者新辅助化疗预后不良的风险较高,且TNM分期为Ⅲ期、BMI高、血清HER2水平高、血清HA水平高均可能为其预后不良的影响因素。

Objective To investigate the influencing factors of poor prognosis in patients with breast cancer after neoadjuvant chemotherapy.Methods A total of 107 breast cancer patients who received neoadjuvant chemotherapy in Zhoukou Hospital of Traditional Chinese Medicine from June 2018 to February 2020 were selected as the research subjects.All patients were followed up for 1 year after 6 cycles of treatment,and their prognoses were evaluated.The baseline data questionnaire was designed to record general data,and the influencing factors of poor prognosis in breast cancer patients after neoadjuvant chemotherapy were analyzed.Results Followed up for 1 year after operation,22 of 107 patients(20.56%)with BC died from illness,and the 22 patients were included into the death group;the other 85 patients were included into the survival group.The proportion of TNM stageⅢin the death group was higher than that in the survival group,and body mass index(BMI),the levels of serum human epidermal growth factor receptor 2(HER2),and serum hyaluronic acid(HA)in the death group were higher than those in the survival group(P<0.05).The results of Cox regression analysis showed that,TNM stageⅢ,HER2 positive,high BMI and serum HA levels were risk factors for poor prognosis in breast cancer patients after neoadjuvant chemotherapy(P<0.05).Conclusions Patients with breast cancer have a higher risk of poor prognosis after neoadjuvant chemotherapy.And TNM stageⅢ,high BMI,high serum HER2 level,and high serum HA level may be the influencing factors of poor prognosis.